50 results
SC 14D9
EX-99
GRNA
GreenLight Biosciences Inc
21 Jun 23
Tender offer solicitation
9:27am
Take-Privates Notes: Data sourced from Capital IQ Transactions announced between 2021 – 2023 YTD, 05/26/2023 Issuer/Targets listed on U.S. exchanges … – U.S. listed Take-Privates (Cont.) Notes: Data sourced from Capital IQ Transactions announced between 2021 – 2023 YTD, 05/26/2023 Issuer/Targets listed
424B3
GRNA
GreenLight Biosciences Inc
9 Nov 22
Prospectus supplement
5:27pm
access fee. Under the Development and Option Agreement, the Company may reserve up to three specified targets (“Reserved Targets”) for development … of therapeutic products related to such targets, using the Acuitas LNP Technology. In order to reserve a Reserved Target, the Company must provide
8-K
EX-99
GRNA
GreenLight Biosciences Inc
9 Nov 22
Results of Operations and Financial Condition
5:13pm
includes up to two potential additional vaccine or therapeutic targets.
GreenLight is designing antigens and conducting preclinical research on a potential … : a topical RNA solution that targets the Varroa destructor mite, which threatens the role of honeybees in pollinating more than 100 crops annually
424B3
otydanztf0w48iiw0g9
6 Oct 22
Prospectus supplement
5:15pm
424B3
r04wnof5
26 Sep 22
Prospectus supplement
4:47pm
8-K
EX-99.1
rw9iy92bp09h84crwepl
26 Sep 22
Index to Financial Statements
4:19pm
8-K
EX-99.1
w0avh 5b3
15 Aug 22
GreenLight Biosciences Announces Second Quarter 2022 Financial
6:07pm
424B3
mjvneg78
15 Aug 22
Prospectus supplement
2:17pm
424B3
zz5tv8rh
1 Jun 22
Prospectus supplement
9:06am
424B3
lftc8 6buwqowcqit42
18 May 22
Prospectus supplement
6:33am
424B3
9k181af9myq7qc36ngg8
7 Apr 22
Prospectus supplement
4:02pm
POS AM
vea fq3eyklxtumt
5 Apr 22
Prospectus update (post-effective amendment)
5:18pm
POS AM
EX-10.32
ctw u09pnti
5 Apr 22
Prospectus update (post-effective amendment)
5:18pm